Welcome to Oncternal Therapeutics

 

With a pipeline that includes two clinical-stage products, we’re committed to translate pioneering areas of cancer research into approved therapies that can be used to treat multiple cancer types.

We are working quickly to advance our clinical programs, leveraging our team’s strong experience and a network of academic collaborations.


Lastest Release

 

In the News

 

Clinical-Stage Products
for Rare Cancers

We are recruiting patients

  • With CLL for a Phase 1 study of Cirmtuzumab, our anti-ROR1 monoclonal antibody
  • With Ewing sarcoma for a Phase 1 study of TK216, our small molecule inhibitor of ets-family transcription factor oncoproteins
Participate in Our Trial